Fostamatinib: First Global Approval

Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials

(2018) James Bussel et al.   AMERICAN JOURNAL OF HEMATOLOGY

Effects of ranitidine (antacid), food, and formulation on the pharmacokinetics of fostamatinib: results from five phase I clinical studies

(2016) Talia Flanagan et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Effects of CYP3A4 Inhibitors Ketoconazole and Verapamil and the CYP3A4 Inducer Rifampicin on the Pharmacokinetic Parameters of Fostamatinib: Results from In Vitro and Phase I Clinical Studies

(2016) Paul Martin et al.   Drugs in research & development

Effects of Fostamatinib on the Pharmacokinetics of Oral Contraceptive, Warfarin, and the Statins Rosuvastatin and Simvastatin: Results From Phase I Clinical Studies

(2016) P. Martin et al.   Drugs in research & development

Pharmacokinetic Properties of Fostamatinib in Patients With Renal or Hepatic Impairment: Results From 2 Phase I Clinical Studies

(2015) Paul Martin et al.   CLINICAL THERAPEUTICS

Effects of Fostamatinib on the Pharmacokinetics of Digoxin (a P-Glycoprotein Substrate): Results From in Vitro and Phase I Clinical Studies

(2015) Paul Martin et al.   CLINICAL THERAPEUTICS

Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk

(2008) A. Podolanczuk et al.   BLOOD